JP7877300B2 - 全身性コルチコステロイドによる治療を受けているcopd患者におけるウイルス誘導性増悪を治療するための吸入インターフェロン-ベータの使用 - Google Patents

全身性コルチコステロイドによる治療を受けているcopd患者におけるウイルス誘導性増悪を治療するための吸入インターフェロン-ベータの使用

Info

Publication number
JP7877300B2
JP7877300B2 JP2023515363A JP2023515363A JP7877300B2 JP 7877300 B2 JP7877300 B2 JP 7877300B2 JP 2023515363 A JP2023515363 A JP 2023515363A JP 2023515363 A JP2023515363 A JP 2023515363A JP 7877300 B2 JP7877300 B2 JP 7877300B2
Authority
JP
Japan
Prior art keywords
ifn
copd
patients
administration
pharmaceutical preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023515363A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023540591A5 (cg-RX-API-DMAC7.html
JP2023540591A (ja
Inventor
マースデン,リチャード
モンク,フィリップ
ティアー,ビクトリア
ウィルキンソン,トム
Original Assignee
シナーゲン リサーチ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シナーゲン リサーチ リミテッド filed Critical シナーゲン リサーチ リミテッド
Publication of JP2023540591A publication Critical patent/JP2023540591A/ja
Publication of JP2023540591A5 publication Critical patent/JP2023540591A5/ja
Application granted granted Critical
Publication of JP7877300B2 publication Critical patent/JP7877300B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2023515363A 2020-09-08 2021-09-07 全身性コルチコステロイドによる治療を受けているcopd患者におけるウイルス誘導性増悪を治療するための吸入インターフェロン-ベータの使用 Active JP7877300B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2014114.9 2020-09-08
GBGB2014114.9A GB202014114D0 (en) 2020-09-08 2020-09-08 Use of inhaled interferon-beta to treat virus-induced exacerbations in copd patients undergoing treatment with a systemic corticosteroid
PCT/GB2021/052302 WO2022053792A1 (en) 2020-09-08 2021-09-07 Use of inhaled interferon-beta to treat virus-induced exacerbations in copd patients undergoing treatment with a systemic corticosteroid

Publications (3)

Publication Number Publication Date
JP2023540591A JP2023540591A (ja) 2023-09-25
JP2023540591A5 JP2023540591A5 (cg-RX-API-DMAC7.html) 2024-09-13
JP7877300B2 true JP7877300B2 (ja) 2026-06-22

Family

ID=72841287

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023515363A Active JP7877300B2 (ja) 2020-09-08 2021-09-07 全身性コルチコステロイドによる治療を受けているcopd患者におけるウイルス誘導性増悪を治療するための吸入インターフェロン-ベータの使用

Country Status (7)

Country Link
US (1) US20230241177A1 (cg-RX-API-DMAC7.html)
EP (1) EP4210728A1 (cg-RX-API-DMAC7.html)
JP (1) JP7877300B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230066037A (cg-RX-API-DMAC7.html)
CN (1) CN116249545A (cg-RX-API-DMAC7.html)
GB (1) GB202014114D0 (cg-RX-API-DMAC7.html)
WO (1) WO2022053792A1 (cg-RX-API-DMAC7.html)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007528890A (ja) 2004-03-12 2007-10-18 ユニバーシティ、オブ、サウサンプトン 呼吸器疾患の抗ウイルス療法のためのインターフェロン−β
JP2012512883A (ja) 2008-12-19 2012-06-07 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ウイルス感染の治療における上皮成長因子阻害剤の使用
JP2013522282A (ja) 2010-03-12 2013-06-13 シナーゲン リサーチ リミティッド インフルエンザ様疾患の治療
WO2020128473A1 (en) 2018-12-19 2020-06-25 Imperial College Innovations Limited Novel compounds and their use in therapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6030609A (en) 1995-05-19 2000-02-29 Case Western Reserve University Method and composition for treating paramyxovirus
US7871603B2 (en) 2007-05-18 2011-01-18 Synairgen Research Limited Interferon-beta and/or lambda for use in treating rhinovirus infection in the elderly
WO2015157955A1 (en) * 2014-04-17 2015-10-22 Abbvie Inc. Heterocyclic btk inhibit ors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007528890A (ja) 2004-03-12 2007-10-18 ユニバーシティ、オブ、サウサンプトン 呼吸器疾患の抗ウイルス療法のためのインターフェロン−β
JP2012512883A (ja) 2008-12-19 2012-06-07 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ウイルス感染の治療における上皮成長因子阻害剤の使用
JP2013522282A (ja) 2010-03-12 2013-06-13 シナーゲン リサーチ リミティッド インフルエンザ様疾患の治療
WO2020128473A1 (en) 2018-12-19 2020-06-25 Imperial College Innovations Limited Novel compounds and their use in therapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Lancet,2015年,385(Suppl.1),S88, Poster52,https://www.thelancet.com/action/showPdf?pii=S0140-6736%2815%2960403-2

Also Published As

Publication number Publication date
EP4210728A1 (en) 2023-07-19
US20230241177A1 (en) 2023-08-03
GB202014114D0 (en) 2020-10-21
JP2023540591A (ja) 2023-09-25
WO2022053792A1 (en) 2022-03-17
KR20230066037A (ko) 2023-05-12
CN116249545A (zh) 2023-06-09

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240905

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240905

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250820

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250826

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251120

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260512

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260610

R150 Certificate of patent or registration of utility model

Ref document number: 7877300

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150